Investigation of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of 25 mg BAY 2433334 in Male and Female Participants With Different Stages of Renal Impairment (Including on Dialysis), as Compared to Age, Gender and Weight Matched Participants in a Single-center, Non-randomized, Non-controlled, Non-blinded, Group Stratification Design Study
Latest Information Update: 17 Jan 2022
At a glance
- Drugs Asundexian (Primary)
- Indications Stroke; Thromboembolism
- Focus Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 10 Jan 2022 Results published in the British Journal of Clinical Pharmacology
- 20 Dec 2021 Status changed from active, no longer recruiting to completed.
- 18 Nov 2021 Planned End Date changed from 12 Nov 2021 to 10 Dec 2021.